STD/HIV control in Malawi and the search for affordable and effective urethritis therapy: a first field evaluation. by Lule, G et al.
Genitourin Med 1994;70:384-388
STD/HIV control in Malawi and the search for
affordable and effective urethritis therapy: a first
field evaluation























Ms F Behets, University
of North Carolina at
Chapel Hill, Departnent
of Medicine, 547 Bumett-





Objectives-To evaluate gonococcal (GU)
and nongonococcal urethritis (NGU),
chlamydia antigen, and serostatus for
syphilis and human immunodeficiency
virus (HIV) among males attending a
Malawian STD clinic with complaints of
urethral discharge andfor dysuria. To
collect demographic and behavioural
data and to determine the effectiveness of
five treatments for urethritis.
Methods-Urethritis was diagnosed using
microscopy and culture for Neisseria
gonorrhoeae. Sera were screened with
rapid plasma reagin (RPR) and if reac-
tive, with microhaemagglutination for
Treponema pallidum (MHA-TP). HIV
antibodies and chlamydia antigen were
detected using enzyme niminoassay.
Patients were randomised for treatment,
cure was assessed 8-10 days later.
Results-At enrolment, GU was diag-
nosed in 415 (80.3%) and NGU in 59
(11.2%) of 517 males. Chlamydia antigen
was found in 26 (5.2%) of 497 specimens
tested. Syphilis seropositivity rate (RPR
and MHA-TP reactive) was 10-7%.
Overall HIV seroprevalence was 44.2%;
71-7% of men with reactive syphilis
serology were HIV( +) compared with
40-9% of syphilis seronegatives (OR:
3'6, p < 0.001). Trimethoprim 320 mgl
sulphamethoxazole 1600 mg by mouth for
2 days (TMPSMX), or the combination
of amoxicillin 3 gm, probenicid 1 gm,
and clavulanate 125 mg by mouth once
(APC), failed to cure gonorrhoea effec-
tively. Amoxicillin 3 gm, probenicid 1
gm, and clavulanate 125 mg, by mouth
once with doxycycline 100 mg BID for 7
days (APC-D), gentamicin 240 mg IM
once (GENT), ciprofloxacin 250 mg by
mouth once (CIPRO) cured 92*9% to 95%
of gonorrhoea. APC-D treatment did not
generate less NGU at follow-up. HIV
serostatus did not affect cure of
urethritis.
Conclusion-All patients presenting with
urethritis should be treated syndromi-
cally using a simple algorithm and
screened for syphilis seroreactivity for
appropriate treatment and counselling.
(Genitourin Med 1994;70:384-388)
Introduction
The World Health Organisation's (WHO)
Global Program on AIDS (GPA) estimated
by mid-1993 that of the 13 million cumulative
HIV infections in adults and youth world-
wide, more than 8 million occurred in Africa.'
Numerous cross-sectional and prospective
studies provide consistent evidence that non-
ulcerative as well as ulcerative sexually trans-
mitted diseases (STDs) are associated with a
3- to 5-fold increased risk of HIV transmis-
sion.2 Although the relative risk for transmis-
sion of HIV infection might be higher for
ulcerative diseases, in many settings the
attributable risk associated with gonococcal
and chlamydial infections will be more con-
sequential.2 Indeed, according to WHO esti-
mates for 1991, 29.9% of 250.5 million new
cases of classic STDs (that is, all STDs except
HIV) worldwide were due to gonococcal and
chlamydial infections compared with 2.2%
for syphilis and chancroid.3 Adequate control
of these infections has become an essential
component of most HIV prevention pro-
grammes.4
Malawi has high HIV infection rates. At the
Blantyre Queen Elisabeth Central Hospital
(QECH), HIV-1 seropositivity was 23%
among 6,600 antenatal women in
1989-1990,5 and between 15% and 30%
among blood donors in 1988.6 In Lilongwe,
62A4% of 705 adult outpatients with signs or
symptoms associated with STDs had HIV
antibodies in 1989.6
Sexually transmitted infections other than
HIV are widespread in Malawi, although less
well documented.6 A 4.4% prevalence of
STDs was found among adult outpatients
presenting at the Kamuzu Central Hospital in
Lilongwe, Malawi. This underestimates the
true prevalence because the study design did
not allow detection of asymptomatic STDs,
and laboratory diagnosis was limited.6 Among
the 6,600 women mentioned earlier who were
seeking antenatal care in Blantyre, 42% were
diagnosed with a classic STD.5
Effective STD control requires proper
diagnosis and case management. Syndromic
approaches using simple algorithms have been
advocated.' Knowledge of local factors such
as relative contribution of aetiological agents
associated with specific syndromes, effective-
ness of antimicrobial therapies, and behav-
ioural observations are keys to optimal design
and use of syndromic approaches. During the
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recent launching of its STD control pro-
gramme, the Malawian AIDS Secretariat in
collaboration with other scientists, found that
39% of the gonococcal isolates produced
penicillinase and evaluation of in vitro anti-
microbial susceptibility was started (personal
communication, Dr Dallabetta).
This study was undertaken to determine
the relative contribution of Neisseria gonor-
rhoeae and Chlamydia trachomatis to urethritis
in Malawi, to evaluate the effectiveness of five
antibiotic therapies for urethritis, and to
determine clinical, demographic and behav-
ioural characteristics of male patients present-
ing with complaints of urethritis in an urban
clinic.
Methods
The study was approved by the Health
Sciences Research Committee of Malawi, by
the Committee on the Protection of the
Rights of- Human Subjects at the University
of North Carolina School of Medicine, and
by the review board of Family Health
International. Antimicrobials previously
described as effective and recorded in the
Malawian national drug formulary were
selected for evaluation together with
ciprofloxacin, a well established gonococcal
therapy. Between September 1992 and March
1993, all males presenting with complaints of
urethral discharge and/or dysuria (even when
no urethral discharge was seen upon examina-
tion) a-t the outpatient clinic of the Queen
Elisabeth Central Hospital in Blantyre,
Malawi, were asked to participate in a
prospective study of urethritis treatment effi-
cacy. Only those patients who had no concur-
rent visible ulcer, and who agreed to return
for a follow-up visit were eligible for enrol-
ment in the study. After obtaining informed
consent from potential study subjects, a
trained nurse administered a structured,
nurse-led questionnaire in the local language
to collect demographic and behavioral data as
well as a selected medical history.
Each participant underwent a physical
examination including urethral stripping to
determine presence of discharge. Urethral
samples were obtained for microscopy of
Gram stained smear, for culture of Neisseria
gonorrhoeae and for EIA chlamydia antigen
detection. Urethral specimens were directly
inoculated onto Thayer-Martin media (BBL,
Becton-Dickinson, USA) and immediately
placed in candle extinction jars with moisture
pads. Cultures were incubated at 36°C and
inspected for growth indicative of Neisseria
gonorrhoeae after 24 and 48 hours. A Gram
stain was performed on oxidase positive
colonies with characteristic morphology, and
pure subcultures were frozen for further
analyses. A patient was diagnosed with gono-
coccal urethritis (GU) if Gram negative intra-
cellular diplococci were found in the urethral
smear and/or if the culture was positive.
Chlamydia antigen detection was carried out
using EIA (Antigenz EIA, Shield Diagnostics
Ltd, UK) following the instructions of the
manufacturer. A patient was diagnosed with
nongonococcal urethritis (NGU) when the
culture for Neisseria gonorrhoeae remained
negative and when at least five polymor-
phonuclear cells were observed per high
power field in the direct urethral smear in the
absence of Gram negative intracellular diplo-
cocci. Patients who had less than 5 polymor-
phonuclear cells per high power field, and had
no evidence of gonococcal urethritis but had a
positive chlamydia antigen detection test were
also diagnosed with NGU.
Blood was collected by venipuncture for
screening of sera with rapid plasma reagin
(RPR) (Macro-Vue, Becton-Dickinson,
USA). RPR reactive sera were diluted to
determine endpoint reactivity and were tested
with microhemagglutination for Treponema
pallidum (MHA-TP) (SeraTec Treponemal
Antibody, Fujeribio, Miles, USA).
Upon completion of the study, linked,
anonymous testing for HIV antibodies using
Wellcozyme ETA (Wellcome, UK) was carried
out on stored sera. Reactive sera underwent
repeat testing.
Patients were randomised using comput-
erised randomisation assignments in sealed
envelopes to one of the following treatment
arms: 1. Amoxicillin 3 gm, probenicid 1 gmi,
and clavulanate 125 mg by mouth once
(APC), 2. Amoxicillin 3 gmi, probenicid 1 gm,
and clavulanate 125 mg, by mouth once and
doxycycline 100 mg BID for 7 days (APC-D),
3. Gentamicin 240 mg IM once (GENT),
4. Ciprofloxacin 250 mg by mouth once
(CIPRO), 5. Trimethoprim 320 mg/
sulphamethoxazole 1600 mg by mouth for 2
days (TMPSMX)
All patients were asked to return 8-10 days
after the initial visit for assessment of symp-
toms and signs. A physical examination was
performed as described above to determine
presence of discharge, and a specimen for ure-
thral Gram stain and culture was obtained.
Chlamydial antigen was evaluated only if the
symptoms persisted.
dBASE III PLUS was used for data entry.
SAS statistical software for analyses.
Comparisons of rates were carried out using
Mantel-Haenszel chi-square, Fisher's exact,
the nonparametric Wilcoxon test was used for
ordinal data.
Results
A total of 517 male subjects were enrolled
in the study. The mean age of the study
participants was 27x3 years (range: 13-70,
SE: 0.35) with an average of 5-4 years
(SE: 0. 19) of education completed. The mean
duration of reported symptoms at initial visit
was 8-7 days (range: 1-85, SE: 0.76), 12-2%
of the patients reported presence of symptoms
for at least two weeks. When asked about
care-seeking behaviour for the current episode
of urethritis, 53% of the patients reported
having sought treatment elsewhere: 36-5%
had consulted a traditional healer or herbalist,
31.0% had gone to a pharmacist, 22-7% to
another clinic or private physician, and 29.7%
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History ofSTD in past 2 years
History of STD in past 6 months
> 1 sex partner in past month
Sex with bargirl in past month
Sex with a new partner in past m
reported other unspeci
ment. Some patients t
sought more than one
Additional behavioural
characteristics of the si
described in table 1. Re
with a bargirl (commel
not correlate with emplc
tus.
Purulent discharge
71.4% of the patients, 2
charge, and 1.3% had
(a) Cure rates of urethritis according to symptoms rel
Number of % No % Decrd
Therapy(*) patients symptoms sympton
APC 76 61-8 29-0
APC-D 74 78-4 12-2
GENT 60 66-7 25-0
CIPRO 74 77.0 10-8
TMPSMX 41 53-7 31-7
Total 325 68-9 20-6
(b) Cure rates of urethritis according to occurrence of laborator
follow-up visit
Number of % NGE
Therapy(*) patients % Cured PGU(*
APC 71 56-3 15-5
APC-D 68 73-5 20-6
GENT 53 73-6 22-6
CIPRO 70 61-4 28-6
TMPSMX 35 51-4 5.7
Overall 297 65-6 20-2
(*) See text for abbreviations and definitions.
|ii!/%cured
APC APC-D GENT
Figure Cure rates of laboratory confirmed gonococcal urethrit
cle patients with urethritis Scrotal pain was reported by 29 1% of the
[alawi between September patients and scrotal swelling by 1.8%.
Four hundred and fifteen (80.3%) of 517
% patients had gonococcal urethritis, and 59
46-2 (11.5%) had nongonococcal urethritis.
4753 Chlamydia antigen was found in 26 (5.2%) of
70-2 the 497 specimens tested; the total chlamydia
13.6 and gonococcal co-infection rate was 2-4%.
22.3
Q8-9 Gonococcal urethritis was diagnosed in
13 9 63 1% of patients with mucoid discharge64.4
tonth 39 compared with 86.3% in patients with puru-
lent secretion (OR: 0-27, 95% CI: 0.16-0.45;
p = 0 008). Sixty one (12.2%) of 502 evalu-
ified forms of treat- ated sera were RPR reactive, the overall pro-
thus reported having portion of RPR and MHA-TP positive sera
form of treatment. was 10-7%.
and demographic Of the 517 patients enrolled in the study,
tudy participants are 330 (63.8%) returned for their follow-up visit.
ported sexual contact Men who reported previous use of pills for the
rcial sex worker) did current episode of urethritis were less likely to
)yment or marital sta- return for follow-up (OR: 0 59; 95% CI:
040-0.85; p = 0 005). Age, circumcision,
was observed among duration of symptoms, sexual contact with
7-2% had mucoid dis- prostitute, marital and employment status,
no visible secretion. and HIV serostatus did not differ between
patients who retumed and those who were
ported by patients at follow- lost to follow-up. There were no differences in
follow-up rates between treatment arms. On
eased % Samel average, the patients returned after 9 5 days
ns worse (1-44 days, median 8 days).
9-2 The clinical effects of therapy on all ureth-
9.5 ritis patients are shown in the first part of
12-2 table 2. The best results as reported by the
146 patients were obtained with APC-D or
CIPRO, followed by GENT and APC. Only
urethritis at 53-7% of the patients treated with TMPSMX
reported resolution of symptoms at the
1/ follow-up visit. Treatment with trimetho-
% GU(*) prim/sulfamethoxazole was stopped before
28*2 completion of the study when its poor cure529 rate became obvious during an interim data
3.8 analysis by an independent observer.
42-9 The effects of therapy on all urethritis
14-2 patients were further analysed based on labo-
ratory data at follow-up as shown in the sec-
ond part of table 2. Occurrence ofNGU/PGU
at follow-up was not lower in patients treated
with APC-D, the only regimen with doxy-
cycline. Chlamydia antigen was detected in
55/59 three (5.8%) of 55 patients presenting with
*....... *****persistent symptoms at follow-up visit.
:*:.:e:9:.:.:w:.:.: The effects of therapy on laboratory-proven
gonorrhoea are shown in the fig. APC-D,
GENT, and CIPRO were effective at treating
:.:@:.:.:*.:@:.:.:.. gonorrhoea. Confirmed gonococcal urethritis
was clearly inadequately cured using
TMPSMX or using APC. Among those
....@.@.-.. 14/29 patients who reported complete disappear-
ance of symptoms, 10.6% had laboratory evi-
........... :dence of gonococcal infection. Indeed, of the
48 patients with persistent gonococcal infec-
::::::::::::::: ::::::: : tion at follow-up visit, 14-6% of the patients.@...@.@..@.-.. ..-..@..*..s..-.... ...........*@@@. - . ..@:::::::::::. :::::::: reported same or worse symptoms, 39-6%
* @ @@ - @ . . ..........@ @@
. ... @ ...... . ....... . .........::.:: reported decreased symptoms, and 45-8%
.. . . . . . . . . . . . . . . . . . . ... ................ ......::::: ::@:@:@e:i:.... reported complete dissipation of initial com-
*@......... ....... . .
......... . ....................*.:::::~~~ plaints. Among these 48 patients, 6 (12.5%)......... . .........-reported having had sex between initial andCIPRO TMPSMX follow-up visit, compared with 21 (8.4%) of
249 men for whom gonococcal infection was
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Two hundred and twenty eight (44.2%) of
516 patients evaluated had HIV antibodies by
EIA. Men between 25-29 years old had the
highest rate of seropositivity (58 1%).
Employed men were more likely to be
seropositive than unemployed, with HIV
prevalence rates of 47-5% and 36.0% res-
pectively (OR: 1-6, 95% CI: 1.09-2.38;
p = 0.02). Men reporting alcohol use showed a
higher HIV rate: 55.2%, than men who did
not report alcohol use: 31.7% (OR: 2.6,
95% CI: 1.85-3.80; p < 0-001). Although
reported sexual contact with a bargirl and lack
of circumcision were associated with a higher
HIV seroprevalence, these differences were
not statistically significant at the 0.05 level.
The highest HIV seroprevalence was found
among patients with a positive syphilis serol-
ogy: 71.7% as compared with 40.9% among
patients with negative syphilis serology (OR:
3.6, 95% CI: 2.01-6.65; p < 0.001). Cure
rates defined by absence of laboratory con-
firmed urethritis at follow-up visit did not dif-
fer significantly between HIV seropositive
(64.2%) and HIV seronegative patients
(65%). Similarly, clearance of symptoms as
reported by patients at follow-up did not dif-
fer significantly between HIV seropositive and
HIV seronegative patients.
Discussion
In this study, infection with Neisseria gonor-
rhoeae was confirmed in 80.3% of all patients
presenting with complaints of urethral dis-
charge and/or dysuria, whereas Chlamydia tra-
chomatis (as determined by direct antigen
detection using EIA) was not a major
pathogen. A similarly low prevalence of
chlamydia (34-4%) was found among preg-
nant women in Blantyre.5 Among patients
symptomatic at follow-up visit we also
detected few carriers of chlamydia antigen.
We did not screen for other organisms associ-
ated with NGU such as Ureaplasma urea-
lyticum and Trichomonas vaginalis.
At enrolment, complaints of dysuria and/or
urethral discharge among our study partici-
pants were highly specific for laboratory con-
finned urethritis. In this setting, the
syndromic approach for management of
patients presenting with complaints of dysuria
and/or urethral discharge using a simple
algorithm requires no laboratory analyses
except syphilis screening. Our findings are not
applicable for asymptomatic patients who do
require laboratory diagnosis for detection.
For instance, in a community-based study in
Tanzania, asymptomatic infection was found
in 90% of men infected with gonorrhoea or
chlamydia.7 The importance of using effective
therapy was illustrated at follow-up where we
documented that 85% of the men who had
gonococcal infection reported complete
resolution or substantial improvement of
symptoms.
Trimethoprim 320 mg/sulphamethoxazole
1600 mg PO for 2 days or amoxicillin 3 gm,
probenicid 1 gm, and clavulanate 125 mg PO
once were ineffective for treatment of gono-
coccal urethritis. The failure rates were 51.7%
and 33.3% respectively. Possible reasons for
treatment failure such as lack of compliance
or vomiting cannot be determined. First doses
of all oral treatments were taken under direct
supervision of the nurse, but patients' compli-
ance for the second dose of TMPSMX was
not directly measured. The three other evalu-
ated regimens: APC-D, GENT, and CIPRO
all appear equally effective for gonococcal
urethritis with failure rates ranging between
5% and 7.1%.
It is plausible that the urethritis cure rates
we observed represent an under-estimate of
the real cure rates. Indeed, our treatment fail-
ure rates might be higher than we would have
observed had all enrolled patients returned for
follow-up. Although we did not find signifi-
cant differences in follow-up rates between
treatment arms, patients with prompt
response to therapy might be less likely to
return for follow-up. In a simultaneously con-
ducted study at the same clinic, we observed
an overall follow-up rate among patients with
genital ulcer disease (which usually needs
more time to cure than urethritis) of 70.2%,
compared with 63.8% among patients with
urethral discharge (p = 0.02) (manuscript in
preparation).
The only doxycyclin-inclusive regimen,
APC-D, failed to show a lower NGU rate at
follow-up than the other regimens although it
reduced urethral symptoms best according to
patient reporting. Poor response of Chlamydia
trachomatis-negative NGU to antimicrobials
which are active against C trachomatis has
been described.8
Over and Piot have demonstrated that
STD control interventions can be highly cost-
effective.9 They calculated that the cost per
discounted disability-adjusted life-year saved
can be as low as US $0.56 for a classic STD
control programme aimed at "core groups" or
high frequency transmitters. While cost-effi-
ciency calculations provide the rationale for
investment in STD control, many developing
countries suffer from severe scarcity of
resources at the national and individual level.
Malawi's per capita GNP of US $230, and
per capita total health expenditure of
US $1110 mandate effective STD therapy at
the lowest cost possible. Antimicrobial regi-
mens currently recommended by the World
Health Organization for treatment of gonor-
rhoea such as ciprofloxacin 500 mg or ceftri-
axone 250 mg, are expensive. In the United
States Public Health Services, ceftriaxone 125
mg intramuscularly is recommended for treat-
ment of uncomplicated gonorrhoea." Even
this reduced treatment format remains costly
and might be incompatible with many
national health budgets. Following comple-
tion of this study, the Malawian STD
Advisory Committee decided to select gen-
tamicin 240 mg IM once together with doxy-
cycline 100 mg BID for 7 days as the
nationally recommended regimen of choice
for urethritis. While the results of this study
do not necessarily support the use of doxy-
cycline, concurrent use of gentamycin and
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doxycycline might help delay the emergence
of gonococcal resistance to gentamycin. The
disadvantages and risks associated with injec-
tion-requiring gentamycin and the need for
sterile needles and syringes were weighed
against the local cost of this regimen at US
$0.77 compared with US $1-5 to 2.2 for the
other identified effective regimens.
As expected, HIV seroprevalence was high
among these patients. Higher socio-economic
status as measured by husband's education,
was a risk factor for HIV infection among
pregnant women in Blantyre.5 Among our
STD patients we found that employed men
and men reporting current alcohol use were at
increased risk of being HIV seropositive. We
also documented that more than two out of
three of the male urethritis patients who had a
positive syphilis serology were HIV seroposi-
tive. Systematic syphilis screening of all ure-
thritis patients is thus crucial for appropriate
treatment including education and coun-
selling. Although our sample size does not
allow definitive conclusions, the finding that
cure of uncomplicated gonorrhoea was not
affected by concurrent HIV infection is
encouraging.
In this study, 53% of all participants pre-
sented at the public STD clinic (where all ser-
vices and drugs are provided free of cost) had
first sought care elsewhere for their episode of
urethritis. Although we can only speculate
about the reasons for this, it does demonstrate
the frequency of inadequate care at the first
visit. Among our study participants who had
sought care elsewhere, more than one out of
three reported having consulted a traditional
healer or herbalist. Traditional healers have
been reported to be perceived as less expen-
sive, more sympathetic, more confidential,
and more easily accessible.'2 That adequate
care can increase clinic use without special
promotional or educational efforts has been
confirmed at this STD clinic in Blantyre
where attendance has tripled (personal obser-
vation, G. Lule) since an effective regimen is
given routinely.
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